- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
CheckMate 77T: Perioperative Immunotherapy in Resectable NSCLC
Patrick Forde, MBBCh, shares insights on perioperative immunotherapy in the CheckMate-77T study presented at ESMO 2023.
EP: 1.CheckMate 77T: Perioperative Immunotherapy in Resectable NSCLC
EP: 2.Evolving NSCLC Landscape: Comparing Recent Updates in Neoadjuvant and Perioperative Immunotherapy
EP: 3.Updates in ALK+ NSCLC: ALINA Trial at ESMO 2023
EP: 4.Lessons from LIBRETTO-431 Trial in RET+ NSCLC
EP: 5.PAPILLON Trial Insights: ESMO 2023
EP: 6.Innovations Needed and Future Directions in Treatment of NSCLC
This is a video synopsis/summary of a Post Conference Perspectives involving Patrick Forde, MBBCh.
In this video, Forde discusses recent advances in the treatment of non–small cell lung cancer (NSCLC). He notes that over the past decade, management of NSCLC has dramatically changed with the introduction of targeted therapies and immunotherapy. NSCLC can be characterized by targetable molecular alterations for first-line therapy in advanced disease. However, many patients still do not respond to initial therapies. Addition of systemic therapy in early-stage, surgically resectable disease is also an unmet need.
Forde discusses results from CheckMate-77T (NCT04025879), the third trial of perioperative immunotherapy in NSCLC. In this phase 3 trial, 461 patients with stage II to IIIB NSCLC without targetable mutations were randomly assigned 1:1 to neoadjuvant nivolumab (anti–PD-1) with platinum-doublet chemotherapy followed by surgery and adjuvant nivolumab, or placebo with platinum-doublet chemotherapy followed by surgery and adjuvant placebo. The majority underwent planned surgery. The study met its primary end point, with nivolumab significantly improving event-free survival and pathologic complete response rate.
Forde notes this is the third positive trial showing benefit of perioperative immunotherapy in NSCLC. Results support moving away from postoperative therapy alone to strongly considering neoadjuvant immunotherapy plus adjuvant therapy for NSCLC. Data from other cancers suggest potential benefit from the neoadjuvant phase.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
